12.80Open12.80Pre Close0 Volume871 Open Interest250.00Strike Price0.00Turnover44.02%IV3.14%PremiumDec 20, 2024Expiry Date5.11Intrinsic Value100Multiplier27DDays to Expiry7.69Extrinsic Value100Contract SizeAmericanOptions Type-0.5351Delta0.0135Gamma17.19Leverage Ratio-0.1999Theta-0.0945Rho-9.20Eff Leverage0.2676Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet